Does the Khorana Risk Score accurately predict the risk of venous thromboembolism in patients with NSCLC and SCLC?
The Khorana Risk Score is insufficient on its own for predicting VTE in lung cancer patients, highlighting the need for updated risk stratification tools that incorporate additional clinical parameters.
This study highlights the limitations of the KRS in predicting risk of development of VTE in patients with NSCLC and SCLC and identifies multiple clinical parameters associated with increased risk of VTE. Development of further risk stratification tools incorporating these clinical factors in addition to those in the KRS should be considered.
Dougherty et al. (2026) studied this question.